Bright Minds Biosciences (DRUG) vs Puma Biotechnology (PBYI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Puma Biotechnology (PBYI) has outperformed Bright Minds Biosciences (DRUG) over the past year, gaining 97.5% versus a loss of 12.0%. Over five years, PBYI leads with a +70.1% price change compared with +45.5% for DRUG. Bright Minds Biosciences is the larger company by market cap ($533.2 million vs $531.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DRUG | PBYI |
|---|---|---|
| Share price | $54.05 | $10.29 |
| Market cap | $533.15M | $531.17M |
| 1-day change | +3.94% | +3.21% |
| YTD return | -30.74% | +72.94% |
| 1-year return | -11.99% | +97.50% |
| 5-year return | +45.49% | +70.08% |
| P/E ratio (TTM) | — | 20.18 |
| Forward P/E | — | 29.40 |
| EPS (TTM) | $-2.05 | $0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $123.75 | $10.36 |
| 52-week low | $47.23 | $4.58 |
| Distance from 52-week high | -56.32% | -0.68% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +181.17% | — |
| Average volume | 155.37K | 320.08K |
| Shares outstanding | 9.86M | 51.62M |
| Employees | 26 | 179 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PBYI has outperformed DRUG by 109.5 percentage points over the past year.
About Bright Minds Biosciences
DRUG stock →Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies.
Health Care · Biotechnology: Pharmaceutical Preparations · 26 employees
About Puma Biotechnology
PBYI stock →Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.
Health Care · Biotechnology: Pharmaceutical Preparations · 179 employees
DRUG vs PBYI FAQ
Which is bigger, Bright Minds Biosciences or Puma Biotechnology?
Bright Minds Biosciences (DRUG) is larger, with a market capitalization of $533.15M compared with $531.17M for Puma Biotechnology (PBYI).
Which stock has performed better over the past year, DRUG or PBYI?
PBYI returned +97.50% over the past 12 months, compared with -11.99% for DRUG (price return, excluding dividends). Past performance does not predict future results.
Are Bright Minds Biosciences and Puma Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.